Provectus Biopharmaceuticals, Inc.
PVCT
$0.0799
-$0.0024-2.92%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -32.72% | 11.33% | 10.67% | 20.39% | -19.21% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -32.72% | 11.33% | 10.67% | 20.39% | -19.21% |
| Cost of Revenue | 25.18% | 4.83% | 15.08% | 13.06% | -4.54% |
| Gross Profit | -62.23% | -1.37% | -17.23% | -8.66% | -8.02% |
| SG&A Expenses | 298.39% | 278.42% | 92.20% | -6.91% | -17.43% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 123.85% | 101.35% | 49.32% | 4.67% | -9.63% |
| Operating Income | -175.85% | -127.33% | -57.95% | -0.32% | 5.92% |
| Income Before Tax | -130.29% | -95.07% | -53.53% | 4.49% | 10.25% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -130.29% | -95.07% | -53.53% | 4.49% | 10.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -128.16% | -94.30% | -53.53% | 4.49% | 10.25% |
| EBIT | -175.85% | -127.33% | -57.95% | -0.32% | 5.92% |
| EBITDA | -176.87% | -128.06% | -58.23% | -0.32% | 5.92% |
| EPS Basic | -128.79% | -93.94% | -52.70% | 4.00% | 10.81% |
| Normalized Basic EPS | -155.88% | -121.21% | -61.54% | -5.88% | 2.86% |
| EPS Diluted | -128.79% | -93.94% | -52.70% | 4.00% | 10.81% |
| Normalized Diluted EPS | -155.88% | -121.21% | -61.54% | -5.88% | 2.86% |
| Average Basic Shares Outstanding | 0.16% | 0.12% | 0.07% | 0.03% | 0.01% |
| Average Diluted Shares Outstanding | 0.16% | 0.12% | 0.07% | 0.03% | 0.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |